Table 1.
Inhibition data for the target compounds on human CA isoforms hCA II and hCA IX.
|
|
||||
|---|---|---|---|---|---|
| 5a–n | 6a–e, h–k | ||||
| Compound | m-/p-1 | n | R | IC50(nM) 2 | |
| hCA II | hCA IX | ||||
| 5a | p- | 0 | -COOH | 113.08 | 216.89 |
| 5b | m- | 0 | -COOH | 134.90 | 254.17 |
| 5c | p- | 0 | -SO2NH2 | 41.58 | 40.58 |
| 5d | m- | 0 | -SO2NH2 | 64.34 | 73.56 |
| 5e | p- | 0 | -COCH3 | 132.38 | 274.81 |
| 5f | p- | 0 | -COOCH3 | 147.28 | 189.52 |
| 5g | m- | 0 | -COOCH3 | 237.54 | 251.03 |
| 5h | p- | 2 | -SO2NH2 | 21.19 | 46.19 |
| 5i | p- | 0 | -SO2NHCH3 | 76.70 | 100.25 |
| 5j | p- | 0 |
|
87.68 | 77.67 |
| 5k | p- | 0 | -SO2NHCOCH3 | 155.91 | 226.58 |
| 5l | p- | 0 |
|
74.21 | 68.78 |
| 5m | p- | 0 |
|
95.90 | 71.02 |
| 5n | p- | 0 |
|
98.41 | 102.54 |
| 6a | p- | 0 | -COOH | 295.94 | 194.02 |
| 6b | m- | 0 | -COOH | 273.78 | 165.92 |
| 6c | p- | 0 | -SO2NH2 | 68.34 | 34.88 |
| 6d | m- | 0 | -SO2NH2 | 91.16 | 55.87 |
| 6e | p- | 0 | -COCH3 | 262.04 | 167.58 |
| 6h | p- | 2 | -SO2NH2 | 61.76 | 30.06 |
| 6i | p- | 0 | -SO2NHCH3 | 172.07 | 110.05 |
| 6j | p- | 0 |
|
189.50 | 61.18 |
| 6k | p- | 0 | -SO2NHCOCH3 | 170.48 | 140.16 |
| AAZ 3 | - | - | - | 26.81 | 49.31 |
1 m- means meta-, p- means para-. 2 IC50 values were determined by the 4-nitrophenyl acetate (4-NPA) esterase assay (errors were in the range of ±5–10% of the reported values). 3 AAZ = acetazolamide.